$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021009283 Filed on May 06, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$72.00K	$68.00K
YoY Change	5.88%	9.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.235M	$1.486M
YoY Change	50.4%	8.06%
% of Gross Profit
Research & Development	$3.279M	$2.706M
YoY Change	21.18%	2.17%
% of Gross Profit
Depreciation & Amortization	$119.0K	$119.0K
YoY Change	0.0%	-6.14%
% of Gross Profit
Operating Expenses	$5.514M	$4.192M
YoY Change	31.54%	4.18%
Operating Profit	-$5.442M	-$4.124M
YoY Change	31.96%	4.1%
Interest Expense	$260.0K	$40.00K
YoY Change	550.0%
% of Operating Profit
Other Income/Expense, Net	$263.0K	-$3.000K
YoY Change	-8866.67%	-249.25%
Pretax Income	-$5.180M	-$4.090M
YoY Change	26.65%	4.87%
Income Tax
% Of Pretax Income
Net Earnings	-$5.179M	-$4.089M
YoY Change	26.66%	4.72%
Net Earnings / Revenue	-7193.06%	-6013.24%
Basic Earnings Per Share	-$0.14
Diluted Earnings Per Share	-$0.14	-$412.7K
COMMON SHARES
Basic Shares Outstanding	37.16M shares	10.21M shares
Diluted Shares Outstanding	37.16M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$125.6M	$9.300M
YoY Change	1250.54%	-17.7%
Cash & Equivalents	$14.66M	$9.277M
Short-Term Investments	$110.9M
Other Short-Term Assets	$2.700M	$900.0K
YoY Change	200.0%	0.0%
Inventory
Prepaid Expenses	$2.744M	$899.5K
Receivables	$242.0K	$106.4K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$128.6M	$10.28M
YoY Change	1150.33%	-16.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$504.0K	$758.5K
YoY Change	-33.55%	158.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$238.0K	$156.4K
YoY Change	52.2%	79.58%
Total Long-Term Assets	$1.003M	$1.532M
YoY Change	-34.55%	-30.24%
TOTAL ASSETS
Total Short-Term Assets	$128.6M	$10.28M
Total Long-Term Assets	$1.003M	$1.532M
Total Assets	$129.6M	$11.82M
YoY Change	996.64%	-18.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$803.0K	$599.0K
YoY Change	34.06%	28.33%
Accrued Expenses	$2.999M	$3.412M
YoY Change	-12.1%	68.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.479M	$4.881M
YoY Change	-8.24%	48.61%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$191.0K	$139.0K
YoY Change	37.37%	-91.31%
Total Long-Term Liabilities	$191.0K	$139.0K
YoY Change	37.37%	-91.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.479M	$4.881M
Total Long-Term Liabilities	$191.0K	$139.0K
Total Liabilities	$4.756M	$5.672M
YoY Change	-16.15%	17.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$236.7M	-$213.0M
YoY Change	11.12%	8.46%
Common Stock	$4.000K	$8.554K
YoY Change	-53.24%	8.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$124.8M	$6.141M
YoY Change
Total Liabilities & Shareholders Equity	$129.6M	$11.82M
YoY Change	996.64%	-18.7%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$5.179M	-$4.089M
YoY Change	26.66%	4.72%
Depreciation, Depletion And Amortization	$119.0K	$119.0K
YoY Change	0.0%	-6.14%
Cash From Operating Activities	-$5.884M	-$3.374M
YoY Change	74.39%	0.42%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$111.7M
YoY Change
Cash From Investing Activities	-$111.7M	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$1.000M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.263M	$2.456M
YoY Change	-48.57%	-24.25%
NET CHANGE
Cash From Operating Activities	-$5.884M	-$3.374M
Cash From Investing Activities	-$111.7M	$0.00
Cash From Financing Activities	$1.263M	$2.456M
Net Change In Cash	-$116.3M	-$918.0K
YoY Change	12570.92%	646.01%
FREE CASH FLOW
Cash From Operating Activities	-$5.884M	-$3.374M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$5.884M	-$3.374M
YoY Change	74.39%	0.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-35558
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	CARDIFF ONCOLOGY, INC.
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2004382
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	11055 Flintkote Avenue
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021Q1	dei	City Area Code CityAreaCode	858
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	952-7570
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2021Q1	dei	Trading Symbol TradingSymbol	CRDF
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	261000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14662000	USD
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37552129	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130981000	USD
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	110922000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	242000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	320000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2744000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2055000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	128570000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	133356000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	504000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	624000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	343000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	238000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	404000	USD
CY2021Q1	us-gaap	Assets Assets	129573000	USD
CY2020Q4	us-gaap	Assets Assets	134727000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	803000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1366000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2999000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3851000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	635000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	860000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	42000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	42000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4479000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6119000	USD
CY2021Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	78000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	285000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	191000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	156000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	4756000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	6569000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37552000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37552000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36781000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36781000	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	363350000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	361819000	USD
CY2021Q1	crdf	Servicereceivable Servicereceivable	1791000	USD
CY2020Q4	crdf	Servicereceivable Servicereceivable	2171000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-67000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-236680000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-231495000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	124817000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	128158000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	129573000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134727000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	72000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68000	USD
CY2021Q1	us-gaap	Revenues Revenues	72000	USD
CY2020Q1	us-gaap	Revenues Revenues	68000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3279000	USD
CY2020Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2706000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2235000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1486000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	5514000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	4192000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5442000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4124000	USD
CY2021Q1	us-gaap	Interest Income Operating InterestIncomeOperating	57000	USD
CY2020Q1	us-gaap	Interest Income Operating InterestIncomeOperating	36000	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	207000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5179000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4089000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	USD
CY2020Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5185000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4095000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37164000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9910000	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5179000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4089000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-67000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5246000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4089000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	USD
CY2020Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6000	USD
CY2021Q1	crdf	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-5252000	USD
CY2020Q1	crdf	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-4095000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	128158000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	268000	USD
CY2021Q1	crdf	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1263000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-67000	USD
CY2021Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	USD
CY2021Q1	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	380000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5179000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	124817000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	7310000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	177000	USD
CY2020Q1	crdf	Sale Of Stock Value Common And Warrants Net SaleOfStockValueCommonAndWarrantsNet	-1000000	USD
CY2020Q1	crdf	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1456000	USD
CY2020Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	USD
CY2020Q1	crdf	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	293000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4089000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	6141000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5179000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4089000	USD
CY2021Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1000	USD
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	119000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	119000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	268000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	177000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-204000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	207000	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2000	USD
CY2021Q1	crdf	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	380000	USD
CY2020Q1	crdf	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	293000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-166000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-79000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-97000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	183000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-56000	USD
CY2021Q1	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-82000	USD
CY2020Q1	crdf	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-80000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1421000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	89000	USD
CY2021Q1	crdf	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-227000	USD
CY2020Q1	crdf	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-206000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	34000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	11000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5884000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3374000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	114195000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2497000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-111698000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	634000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000000	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1263000	USD
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1456000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1263000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2456000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-116319000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-918000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130981000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10195000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14662000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9277000	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2020Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2021Q1	crdf	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	6000	USD
CY2020Q1	crdf	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	6000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	125600000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5185000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4095000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37164000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9910000	shares
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9025380	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11496978	shares
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	110989000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	72000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	110922000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3613000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3628000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3109000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3004000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	504000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	624000	USD
CY2021Q1	crdf	Lessor Number Of Subleases LessorNumberOfSubleases	3	lease
CY2021Q1	crdf	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	80000	USD
CY2021Q1	crdf	Lessee Operating Lease Annual Rent Increase Percentage LesseeOperatingLeaseAnnualRentIncreasePercentage	0.03
CY2021Q1	crdf	Lessor Number Of Subleases LessorNumberOfSubleases	3	lease
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	95000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	107000	USD
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	101000	USD
CY2020Q1	us-gaap	Sublease Income SubleaseIncome	73000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	-6000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	34000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	261000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	343000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	635000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	860000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	643000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	869000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	240000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	233000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	650000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	303000	USD
CY2021Q1	crdf	Lessee Operating Lease Liability Payments Net Of Sublease Income Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear	347000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	0	USD
CY2021Q1	crdf	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year One LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne	6000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	USD
CY2021Q1	crdf	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo	3000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	659000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	303000	USD
CY2021Q1	crdf	Lessee Operating Lease Liability Payments Net Of Sublease Income Due LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue	356000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	643000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	268000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	177000	USD
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	24333	USD
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	34929	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1768104	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.68
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11572933	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5260992	shares
CY2020Q4	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.19
CY2020	crdf	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P4Y1M6D
CY2021Q1	crdf	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	770833	shares
CY2021Q1	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	1.64
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4490159	shares
CY2021Q1	crdf	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	5.80
CY2021Q1	crdf	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P3Y8M12D

Files In Submission

Name	View Source	Status
0001628280-21-009283-index-headers.html	Edgar Link	pending
0001628280-21-009283-index.html	Edgar Link	pending
0001628280-21-009283.txt	Edgar Link	pending
0001628280-21-009283-xbrl.zip	Edgar Link	pending
crdf-033121exhibit311.htm	Edgar Link	pending
crdf-033121exhibit312.htm	Edgar Link	pending
crdf-033121exhibit321.htm	Edgar Link	pending
crdf-033121exhibit322.htm	Edgar Link	pending
crdf-20210331.htm	Edgar Link	pending
crdf-20210331.xsd	Edgar Link	pending
crdf-20210331_cal.xml	Edgar Link	unprocessable
crdf-20210331_def.xml	Edgar Link	unprocessable
crdf-20210331_htm.xml	Edgar Link	completed
crdf-20210331_lab.xml	Edgar Link	unprocessable
crdf-20210331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2021 Q1 Form 10-Q Financial Statement

#000162828021009283 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2021 Q1 Form 10-Q Financial Statement

#000162828021009283 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf